Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: Evidence for the involvement of plasma IgG, complement C3 and ?2 integrin

Takeda, Yuji; Shiobara, Noriyuki; Saniabadi, Abby R.; Adachi, Masakazu; Hiraishi, Katsuya

doi:10.1007/s00011-004-1253-5

Cited by 59 publications

(67 citation statements)

References 29 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During Adacolumn treatment, the extracorporeal circulation results in complement fragments and immunoglobulins being deposited on the CA beads. These deposits induce the specific adsorption of granulocytes and monocytes, which express complement receptors (CD18/CD11b, Mac-1) and Fc receptors [19]. Since lymphocytes do not express these receptors, almost all CD3 1 lymphocytes pass through the CA bead column [20].…”

Section: Discussionmentioning

confidence: 99%

“…From the results of this study, we postulate that monocytes treated with CA beads act as immune suppressors, because intracellular TGF-b1, C5a, and hepatocyte growth factor (HGF) were either upregulated or released into the blood after treatment with CA beads (Fig. 4) [19,29]. C5a stimulation reduces the mRNA expression of IL-12 p35 and p40, IL-23 p19, and IL-27 p28 [28], which in turn induces the differentiation of naïve T cells into Th1 lymphocytes and cytotoxic Tlymphocytes, which subsequently activates NK cells.…”

Section: Foxp3mentioning

confidence: 89%

“…In our study, apoptotic cells did not appear following treatment with CA beads for 1 h (Takeda unpublished results). However, C5a, which is known as an activator of p38, ERK, and JNK in human monocytes [28], has been shown to be generated on CA beads [19,29,30]. Indeed, release of IL-1 receptor antagonist, which is induced by CA beads treatment, was partly inhibited by PD98059, an ERK inhibitor [31].…”

Section: Foxp3 Induction By Ca Beadsmentioning

confidence: 95%

See 2 more Smart Citations

Induction of Foxp3 expression in T cells by cellulose acetate beads in vitro

Jimma

Takeda

Kaneda

et al. 2010

J of Clinical Apheresis

View full text Add to dashboard Cite

Gene expression of transforming growth factor-beta (TGF-beta) is needed to induce expression of transcription factor forkhead box P3 (Foxp3), which is required for the development and function of regulatory T (Treg) cells. The number of circulating Treg cells and the level of Foxp3 expression increase during granulocyte and monocyte apheresis (GMA), a useful therapy for ulcerative colitis. However, the mechanism underlying GMA-induced Foxp3 expression is unknown. We found that the level of TGF-beta mRNA in peripheral blood mononuclear cells (PBMCs) was augmented just after treatment of peripheral blood with a GMA carrier, cellulose acetate beads, in vitro and that Foxp3 expression in PBMCs increased after culturing these cells for 5 days after the treatment. The augmentation of TGF-beta expression was observed in CD3(-) PBMCs but not in CD3(+) T cells. Furthermore, the increase in Foxp3 expression in T cells depended on co-culture with CD3(-) PBMCs. We conclude that cellulose acetate beads have an ability to induce Foxp3 expression in peripheral blood T cells via augmentation of TGF-beta expression in CD3(-) PBMCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Foxp3mentioning

confidence: 89%

Section: Foxp3 Induction By Ca Beadsmentioning

confidence: 95%

See 1 more Smart Citation

Induction of Foxp3 expression in T cells by cellulose acetate beads in vitro

Jimma

Takeda

Kaneda

et al. 2010

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…Takeda et al [33] incubated human whole blood with the GMA carriers in in-vitro settings and measured significant amounts of IL-1 receptor antagonist (IL-1ra) and hepatocyte growth factor (HGF) released from granulocytes and monocytes that adhered to the carriers (Fig. 6); the amounts released were directly proportional to the number of cells that adhered to the carriers.…”

Section: Release Of Anti-inflammatory Substancesmentioning

confidence: 99%

The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review

Hanai

Takeda

Eberhardson

et al. 2010

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryPatients with active inflammatory bowel disease (IBD) have elevated and activated myeloid leucocytes which infiltrate the colonic mucosa in vast numbers. Myeloid leucocytes such as the CD14 + CD16 + monocytes are major sources of tumour necrosis factor (TNF)-a, and therefore selective granulocyte/monocyte (GM) adsorption (GMA) should promote remission or enhance efficacy of pharmacological therapy. However, studies in IBD have reported both impressive as well as disappointing efficacy outcomes, indicating that patients' demographic factors might determine responders or nonresponders to GMA. Nonetheless, this non-drug intervention has an excellent safety profile, and therapeutic GMA is expected to expand. In this review, attempts have been made to compile an update on the mode of actions (MoA) of the Adacolumn GMA. The MoA of GMA appears to be more than adsorption of excess neutrophils and TNF-producing CD14 + CD16 + monocytes per se. Adsorbed GMs release interleukin (IL)-1 receptor antagonist, hepatocyte growth factor and soluble TNF receptors, which are anti-inflammatory. Additionally, a sustained increase in lymphocytes including the regulatory CD4 + CD25 + T cells (lymphocyte sparing) is seen post-GMA. The impact of GMA on the immune system is potentially very interesting in the context of treating immune-related diseases. Future studies are expected to add intriguing insights to the MoA of GMA.

show abstract

“…Therefore, the effects of granulocytapheresis on L-selectin and CXCR3 should minimize leukocyte accumulation in tissues. Fourth, more recently published data show that neutrophils and monocytes when adsorbed to the Adacolumn cellulose acetate carriers release large amounts of IL-1 receptor antagonist and hepatocyte growth factor that have strong anti-inflammatory and tissue repair actions [36].…”

Section: Discussionmentioning

confidence: 98%

Granulocytapheresis in patients with refractory ocular Behcet's disease

Namba¹,

Sonoda²,

Kitamei³

et al. 2006

J. Clin. Apheresis

View full text Add to dashboard Cite

Intraocular inflammation (uveoretinitis) is one major complication of Behcet's disease (BD) and responds poorly to drug therapy. This open prospective study was to assess the efficacy of selective granulocytapheresis in patients with refractory uveoretinitis of BD. Fourteen patients aged 20-56 years were treated. Granulocytapheresis was done with an Adacolumn filled with cellulose acetate leucocyte carries or beads that adsorb granulocytes and monocytes from the blood in the column. Each patient received 5 Adacolumn sessions at one session/week over 5 consecutive weeks. The study was designed to allow each patient to serve as his or her own control. The total numbers of ocular attacks (OA) were monitored for 6 months before and after 5 Adacolumn sessions. The number of OA (mean +/- SD) per patient for the 6 months before Adacolumn was 4.21 +/- 1.6 and for the 6 months post Adacolumn was 2.93 +/- 1.39 ( P = 0.0275). Nine patients (64%) improved and 5 did not change or worsened. Further, for a sub-group (n = 7) with duration of BD > or =5 years, the number of OA were 4.71 +/- 1.89 for the first 6 months and 2.29 +/- 1.38 for the second 6 months ( P = 0.0054). The corresponding values for a sub-group (n = 7) with duration of BD<5 years were 3.71 +/- 1.25 and 3.57 +/- 1.13, indicating that patients with long duration of BD are better responders. We conclude that granulocytapheresis might be effective and safe for patients with refractory ocular BD. Further studies are necessary to fully evaluate the clinical efficacy of granulocytapheresis for BD.

show abstract

Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: Evidence for the involvement of plasma IgG, complement C3 and ?2 integrin

Abstract: Plasma IgG, C3 derived complement activation fragments and leucocytes CD18 are involved in granulocyte adhesion to CA beads and hence the release of HGF and IL-1ra.

Cited by 59 publications

References 29 publications

Induction of Foxp3 expression in T cells by cellulose acetate beads in vitro

Induction of Foxp3 expression in T cells by cellulose acetate beads in vitro

The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review

Granulocytapheresis in patients with refractory ocular Behcet's disease

Contact Info

Product

Resources

About